Download full-text PDF |
Source |
---|
Pediatr Allergy Immunol
December 2024
French National Reference Center for Angioedema (CREAK), Center of Excellence and Reference (ACARE), Internal Medicine Department, Grenoble Alpes University Hospital, Grenoble, France.
Background: Hereditary angioedema (HAE) in children has specific features and requires multidisciplinary management.
Methods: We performed a literature search and underwent in-depth discussions to provide practical tools for physicians.
Results: HAE is a rare, life-threatening genetic disorder.
Arterioscler Thromb Vasc Biol
December 2024
Lung and Vascular Inflammation Section, Laboratory of Allergic Diseases (E.C.C., A.J.A., A.D., K.M.D.), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, MD.
West Afr J Med
June 2024
Department of Medicine, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria Phone number: 08037756969; Email:
Yale J Biol Med
June 2024
Department of Pathology & Medical Biology, University Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Environmental mismatches are defined as changes in the environment that induce public health crises. Well known mismatches leading to chronic disease include the availability of technologies that facilitate unhealthy diets and sedentary lifestyles, both factors that adversely affect cardiovascular health. This commentary puts these mismatches in context with biota alteration, an environmental mismatch involving hygiene-related technologies necessary for avoidance of infectious disease.
View Article and Find Full Text PDFAnn Hematol
June 2024
PHAR (Partnership for Health Analytic Research), 280 S Beverly Dr, Suite 404, Beverly Hills, CA, 90212, USA.
Crizanlizumab, a monoclonal antibody against P-selectin, has been shown to reduce vaso-occlusive crises (VOCs) compared to placebo in patients ≥ 16 years with sickle cell disease (SCD). However, there have been rare reports of patients experiencing severe pain and subsequent complications within 24 hours of crizanlizumab infusions. These events are defined as infusion-related reactions (IRRs).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!